MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 599228 | Name: 4-Chloroloratadine
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

4-Chloroloratadine is an impurity of Loratadine.

Chemical Structure

4-Chloroloratadine
4-Chloroloratadine
CAS#165739-83-3

Theoretical Analysis

MedKoo Cat#: 599228

Name: 4-Chloroloratadine

CAS#: 165739-83-3

Chemical Formula: C22H22Cl2N2O2

Exact Mass: 416.1058

Molecular Weight: 417.33

Elemental Analysis: C, 63.32; H, 5.31; Cl, 16.99; N, 6.71; O, 7.67

Price and Availability

Size Price Availability Quantity
25mg USD 450.00 2 Weeks
50mg USD 800.00 2 Weeks
100mg USD 1,450.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
4-Chloroloratadine; 4-Chloro loratadine; Loratadine specified impurity C;
IUPAC/Chemical Name
ethyl 4-(4,8-dichloro-5,6-dihydro-11H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-ylidene)piperidine-1-carboxylate
InChi Key
LOTMYBFPXGPIDD-UHFFFAOYSA-N
InChi Code
InChI=1S/C22H22Cl2N2O2/c1-2-28-22(27)26-11-8-14(9-12-26)20-17-6-4-16(23)13-15(17)3-5-18-19(24)7-10-25-21(18)20/h4,6-7,10,13H,2-3,5,8-9,11-12H2,1H3
SMILES Code
O=C(N1CC/C(CC1)=C2C3=CC=C(Cl)C=C3CCC4=C(Cl)C=CN=C4\2)OCC
Appearance
Solid powder
Purity
>95% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.03.00
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 417.33 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Abd el-HS, Colyer CL, Hassan WS, Shalaby A. Utility of 4-chloro-7-nitrobenzofurazan (NBD-CI) for the Spectrophotometric and spectrofluorometric determination of several antihistamine and antihypertensive drugs. J AOAC Int. 2013 Sep-Oct;96(5):968-75. PubMed PMID: 24282933. 2: Parkinson A, Clement RP, Casciano CN, Cayen MN. Evaluation of loratadine as an inducer of liver microsomal cytochrome P450 in rats and mice. Biochem Pharmacol. 1992 May 28;43(10):2169-80. PubMed PMID: 1534660. 3: Reddy KV, Babu JM, Kumar YR, Reddy SV, Kumar MK, Eswaraiah S, Reddy KR, Reddy MS, Bhaskar BV, Dubey PK, Vyas K. Impurity profile study of loratadine. J Pharm Biomed Anal. 2003 Apr 24;32(1):29-39. PubMed PMID: 12852446. 4: Zhong D, Blume H. [HPLC-determination of loratadine and its active metabolite descarboethoxyloratadine in human plasma]. Pharmazie. 1994 Oct;49(10):736-9. German. PubMed PMID: 7816900. 5: Squella JA, Sturm JC, Diaz MA, Pessoa H, Nuñez-Vergara LJ. Polarographic determination of loratadine in pharmaceutical preparations. Talanta. 1996 Dec;43(12):2029-35. PubMed PMID: 18966694. 6: Bhatt PM, Desiraju GR. Form I of desloratadine, a tricyclic antihistamine. Acta Crystallogr C. 2006 Jun;62(Pt 6):o362-3. Epub 2006 May 31. PubMed PMID: 16763328. 7: El-Enany N, El-Sherbiny D, Belal F. Spectrophotometric, spectrofluorometric and HPLC determination of desloratadine in dosage forms and human plasma. Chem Pharm Bull (Tokyo). 2007 Dec;55(12):1662-70. PubMed PMID: 18057737. 8: Anthes JC, Gilchrest H, Richard C, Eckel S, Hesk D, West RE Jr, Williams SM, Greenfeder S, Billah M, Kreutner W, Egan RE. Biochemical characterization of desloratadine, a potent antagonist of the human histamine H(1) receptor. Eur J Pharmacol. 2002 Aug 9;449(3):229-37. PubMed PMID: 12167464. 9: Villani FJ, Magatti CV, Vashi DB, Wong J, Popper TL. N-substituted 11-(4-piperidylene)-5,6-dihydro-11H-benzo-[5,6]cyclohepta [1,2-b]pyridines. Antihistamines with no sedating liability. Arzneimittelforschung. 1986 Sep;36(9):1311-4. PubMed PMID: 2947582. 10: Kaminski JJ, Carruthers NI, Wong SC, Chan TM, Billah MM, Tozzi S, McPhail AT. Conformational considerations in the design of dual antagonists of platelet-activating factor (PAF) and histamine. Bioorg Med Chem. 1999 Jul;7(7):1413-23. PubMed PMID: 10465415. 11: Barnett A, Iorio LC, Kreutner W, Tozzi S, Ahn HS, Gulbenkian A. Evaluation of the CNS properties of SCH 29851, a potential non-sedating antihistamine. Agents Actions. 1984 Jun;14(5-6):590-7. PubMed PMID: 6236679. 12: Merlos M, Giral M, Balsa D, Ferrando R, Queralt M, Puigdemont A, García-Rafanell J, Forn J. Rupatadine, a new potent, orally active dual antagonist of histamine and platelet-activating factor (PAF). J Pharmacol Exp Ther. 1997 Jan;280(1):114-21. PubMed PMID: 8996188.

View History

GSK2018682 HCl

GSK2018682 HCl

AZ1508

AZ1508

Otamixaban HCl

Otamixaban HCl

Padeliporfin potassium

Padeliporfin potassium

PUL-042 component PAM2

PUL-042 component PAM2

Pudafensine

Pudafensine